Stock Update: Merck & Co. Inc. (NYSE:MRK) – Endocyte’s Plunge Ignores Drug’s $2.5B Potential

[at Seeking Alpha] – By David J. Phillips Shares of Endocyte ( ECYT ) fell recently after the company said its lead investigational product, the cancer drug vintafolide – being developed in concert . . . → Read More: Stock Update: Merck & Co. Inc. (NYSE:MRK) – Endocyte’s Plunge Ignores Drug’s $2.5B Potential Similar posts: Pfizer 3rd-qtr profit beats estimates; oncology drugs shine – Pfizer Inc. (NYSE:PFE) [Reuters] – Pfizer Inc reported better-than-expected third-quarter earnings on... Johnson & Johnson (NYSE:JNJ) – U.S. guidelines expand potential uses of J&J TB drug [Reuters] – New federal guidelines expand the range of... Merck & Co. Inc. (NYSE:MRK) – Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices [Business Wire] – Merck , known as MSD outside...